AbbVie, an American publicly traded biopharmaceutical company, agreed to acquire DJS Antibodies, a biotechnology company, for $255m. "We are excited to bring the innovative science behind DJS-002 and the talented team at DJS to AbbVie. This acquisition will deliver new capabilities to enhance our current antibody research activities, an opportunity to strengthen our immunology portfolio, and provide a strong foothold for expanded research efforts in the dynamic bioscience hub in Oxford, UK," Jonathon Sedgwick, AbbVie Vice President.